CIK 0001782303 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Boundless Bio, Inc.
Sign in to watch- Ticker
- BOLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 830751369
- Phone
- (858) 766-9912
- Business address
- 11099 NORTH TORREY PINES ROAD, SUITE 150, LA JOLLA, CA, 92037
- Open-market buys, last 90 days
- $458,375
- in 5 filings
- Open-market sales, last 90 days
- $54,351
- in 1 filing
Net +$404,024. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Purchase | +66,667 | $16.00 | $1.1M | 683,759 |
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Purchase | +133,333 | $16.00 | $2.1M | 1,181,766 |
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −424,908 | 0 | ||
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −586,080 | 0 | ||
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −454,212 | 0 | ||
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −227,920 | 0 | ||
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −164,835 | 0 | ||
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −201,465 | 0 | ||
| 2024-04-02 | ARCH Venture Fund IX, L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −366,301 | 0 | ||
| 2024-04-02 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +189,933 | 189,933 | ||
| 2024-04-02 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +366,300 | 556,233 | ||
| 2024-04-02 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series B Preferred Stock | −3,703,704 | 0 | ||
| 2024-04-02 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series C Preferred Stock | −7,142,857 | 0 | ||
| 2024-03-27 | Lim Jonathan E Director | Grant or award · Stock Option | +13,219 | 13,219 | ||
| 2024-03-27 | Lew Jennifer Director | Grant or award · Stock Option | +13,219 | 13,219 | ||
| 2024-03-27 | Rubin Jami Chief Financial Officer | Grant or award · Stock Option | +32,468 | 32,468 | ||
| 2024-03-27 | Christensen James Director | Grant or award · Stock Option | +13,219 | 13,219 | ||
| 2024-03-27 | Wagner Klaus W. Chief Medical Officer | Grant or award · Stock Option | +41,745 | 41,745 | ||
| 2024-03-27 | Oien Jessica See Remarks | Grant or award · Stock Option | +16,234 | 16,234 | ||
| 2024-03-27 | Brennan Christine Director | Grant or award · Stock Option | +26,438 | 26,438 |
Page 9 of 10 · 185 trades